Champions Oncology, Inc. (CSBR) Balance Sheet

The persistent accumulation of a $80.4 million deficit in retained earnings suggests that the company has struggled to generate sustainable internal capital to fund its growth. This reliance on external financing or operational cash flow to maintain solvency warrants close monitoring, as the current equity position provides a minimal buffer against potential asset impairments or further operating losses.

The presence of $3.4 million in total debt against a backdrop of negative retained earnings suggests that the company may face challenges in securing additional non-dilutive capital. Investors should consider whether this leverage is a strategic necessity for infrastructure maintenance or a sign of limited access to more favorable equity-based funding sources.

With cash levels at $7.1 million as of 2026Q3, the company appears to have limited runway to absorb unexpected shocks in project-based revenue or sudden increases in vivarium operating costs. This liquidity profile implies that the firm is highly sensitive to the timing of client payments and the successful conversion of its service pipeline into cash.